3B BlackBio Dx Ltd

3B BlackBio Dx Ltd

$3BBLACKBIOHealthcare Service ProviderBSE

3B BlackBio Dx Ltd (3BBLACKBIO) last traded at ₹1,254, a market capitalisation of ₹1,077 crore, on a P/E of 19.4. Over the past 52 weeks the stock has ranged between ₹1,084 and ₹1,750. 3B BlackBio Dx Ltd last reported results for the quarter ended Jun 2026, with sales of ₹33.49 crore and net profit of ₹8.98 crore. The next scheduled event is an analyst meet on 29 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.

3B BlackBio Dx Ltd share price and key metrics

Current price
₹1,254
Market cap
₹1,077 cr
Stock P/E
19.4
Book value
₹378
ROE
19.8%
ROCE
25.5%
Dividend yield
0.32%
52w high / low
1750/1084

Metrics as of 25 Aug 2026. Not real time.

3B BlackBio Dx Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹33.49 cr, up 50.7% from ₹22.23 cr a year earlier. Net profit was ₹8.98 cr, down 29.0% year on year.

3B BlackBio Dx Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales29.1525.3922.522.2333.950.3535.4333.49
Expenses12.9810.3214.5810.419.1728.6326.9424.97
Operating profit16.1715.077.9211.8314.7321.728.498.52
OPM %55.47%59.35%35.20%53.22%43.45%43.14%23.96%25.44%
Other income3.443.014.944.325.515.5910.156.14
Interest0.030.020.040.010.040.090.10.1
Depreciation0.270.270.280.280.580.383.891.34
Profit before tax19.3117.7912.5415.8619.6226.8414.6513.22
Tax %22.99%24.17%35.89%20.30%23.34%16.39%33.11%32.07%
Net profit14.8713.498.0412.6515.0422.449.818.98
EPS (₹)17.0715.619.7914.6717.1425.3211.1411.10

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

3B BlackBio Dx Ltd annual results

3B BlackBio Dx Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales22781627496142153
Operating profit150372933505753
OPM %66%46%47%44%52%40%35%
Net profit114322632486056
EPS (₹)151.6642.8934.5537.4055.5768.2764.70

TTM is the trailing twelve months to the most recent quarter.

3B BlackBio Dx Ltd growth and returns

Compounded Sales Growth
10 Years
23%
5 Years
-9%
3 Years
32%
TTM
54%
Compounded Profit Growth
10 Years
68%
5 Years
-12%
3 Years
31%
TTM
13%
Stock Price CAGR
10 Years
61%
5 Years
18%
3 Years
28%
1 Year
-11%
Return on Equity
10 Years
27%
5 Years
18%
3 Years
18%
Last Year
20%

3B BlackBio Dx Ltd shareholding pattern

Promoters held 40.95% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.50% and DIIs 2.15%.

3B BlackBio Dx Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters41.28%41.28%41.28%41.28%41.28%41.27%40.94%40.95%
FIIs3.27%2.68%2.49%2.70%2.64%2.57%2.57%2.50%
DIIs1.96%1.74%1.60%1.76%1.82%1.87%1.98%2.15%
Public53.48%54.29%54.64%54.28%54.26%54.27%54.50%54.40%
No. of shareholders9,58610,16610,34510,61910,70910,50710,61611,049

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Upcoming 3B BlackBio Dx Ltd events

The next scheduled event is an analyst meet on 29 Aug 2026.

  • Analyst meetOne-on-one analyst/investor meeting with Param Capital

See the full results calendar for every Indian company reporting in the next 30 days.

3B BlackBio Dx Ltd corporate filings

  • Analyst/ Investor Meet IntimationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: 3B BlackBio Dx Ltd has issued an intimation regarding an upcoming analyst/investor…

    Read the full analysis
  • Newspaper Publication of Unaudited Financial Results for the quarter ended 30th June, 2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: 3B BlackBio Dx Limited has released its unaudited standalone and consolidated financial…

    Read the full analysis
  • Investor''s PresentationCompany Updatehigh impact
    Filing PDF

    Cruxal's analysis: 3B BlackBio Dx Limited reported Q1 2026-27 consolidated revenue of 33.49 crore, up from…

    Read the full analysis
  • Outcome of Board Meeting held on 13th August, 2026Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: 3B BlackBio Dx Limited reported consolidated financial results for the quarter ended June…

    Read the full analysis
  • 3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and ....Board Meetinglow impact
    Filing PDF

    Cruxal's analysis: 3B BlackBio Dx Limited has formally intimated the BSE regarding a Board of Directors…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track 3B BlackBio Dx Ltd

Cruxal reads every 3B BlackBio Dx Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.